Examining the unique standards and related challenges when assessing the safety and efficacy of cancer immunotherapy candidates.
Luke S. Gill
Advertisement
Articles by Luke S. Gill
Cancer immunotherapies require different standards for evaluating their safety and effectiveness. Understanding these standards-and the other major challenges of immuno-oncology studies-is critical to drug development success.
Advertisement
Latest Updated Articles
Maximizing Immuno-Oncology Clinical Trial SuccessPublished: April 5th 2018 | Updated:
Maximizing Immuno-Oncology Clinical Trial SuccessPublished: May 1st 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials' 2025 State of the Industry Survey
2
The Confidence Trap in Clinical Trials: When Knowing Just Enough Becomes Dangerous
3
Do Phase II Protocol Learnings Help Simplify Phase III Protocol Designs?
4
Beyond the Comment Section: Rebuilding Trust in Vaccines Through Conversation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
